Featured Publications
Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine
Bertoletti N, Chan AH, Schinazi RF, Yin YW, Anderson KS. Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. Protein Science 2019, 28: 1664-1675. PMID: 31301259, PMCID: PMC6699100, DOI: 10.1002/pro.3681.Peer-Reviewed Original ResearchConceptsHIV-1Severe drug toxicityActive antiretroviral therapySuccessful treatment regimenMajor health issueActive triphosphate formHIV-1 drugsReverse transcriptaseHIV-1 reverse transcriptaseAntiretroviral therapyOff-target side effectsTreatment regimenRetroviruses HIV-1Drug toxicityReverse transcriptase enzymeSide effectsRT inhibitorsNew infectionsViral replicationHealth issuesTarget toxicityTriphosphate formNext-generation therapeuticsNRTIsTranscriptase enzyme
2020
Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance
Bertoletti N, Chan AH, Schinazi RF, Anderson KS. Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance. Molecules 2020, 25: 4868. PMID: 33096918, PMCID: PMC7587939, DOI: 10.3390/molecules25204868.Peer-Reviewed Original Research
2019
Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV
Kudalkar SN, Ullah I, Bertoletti N, Mandl HK, Cisneros JA, Beloor J, Chan AH, Quijano E, Saltzman WM, Jorgensen WL, Kumar P, Anderson KS. Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV. Antiviral Research 2019, 167: 110-116. PMID: 31034849, PMCID: PMC6554724, DOI: 10.1016/j.antiviral.2019.04.010.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyBALB/c miceHIV-1C miceT cellsHuman immunodeficiency virus type 1 (HIV-1) infectionImmune deficiency syndrome (AIDS) patientsAntiviral activityNon-nucleoside reverse transcriptase inhibitorNovel non-nucleoside reverse transcriptase inhibitorVirus type 1 infectionDrug-resistant HIV-1Observed serum concentrationsHIV-1 infectionType 1 infectionReverse transcriptase inhibitorNon-nucleoside reversePotent antiviral activityHIV therapeutic agentsSignificant antiviral activitySerum residence timeHIV-1 NNRTIsAntiretroviral therapyClinical benefitSerum concentrations